Protocol Ledger

NCT06422507 · Phase III · COMPLETED

A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

Interventional Phase III clinical trial protocol NCT06422507 sponsored by Bayer in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-29 Enrollment: 333 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06422507
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)333 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06422507
Protocol FieldVerified Registry Value
NCT IdentifierNCT06422507
Consolidated Lead SponsorBayer
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment333 participants (ACTUAL)
Registered Start Date2024-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI